#1 Clinical Trials Search in Europe

Syn321

A new drug called SYN321 is currently being studied in clinical trials for the treatment of knee osteoarthritis. This innovative medication is administered through intra-articular injections directly into the knee joint. The ongoing research aims to evaluate the safety, tolerability, and potential effectiveness of SYN321 in providing relief for patients suffering from this common and often debilitating condition.

Table of Contents

What is SYN321?

SYN321 is a new medication being developed to treat knee osteoarthritis (KOA). It is currently undergoing clinical trials to assess its safety and effectiveness. SYN321 is designed to be administered as an intra-articular injection, which means it’s injected directly into the knee joint.[1]

How Does SYN321 Work?

SYN321 is described as having a local analgesic (pain-relieving) and anti-inflammatory effect. It may also have a potential lubricating effect on the knee joint. The active substance in SYN321 is related to diclofenac, which is a well-known non-steroidal anti-inflammatory drug (NSAID). However, SYN321 has been specially formulated to be injected directly into the knee, potentially providing targeted relief for osteoarthritis symptoms.[1]

Clinical Trial Details

The clinical trial for SYN321 is a Phase 1/2a study, which means it’s in the early stages of testing in humans. Here are some key details about the trial:
  • It’s a prospective, double-blinded, randomized, placebo-controlled study. This means that participants will be randomly assigned to receive either SYN321 or a placebo, and neither the participants nor the researchers will know who is receiving which treatment until the study is complete.
  • The main goal is to evaluate the safety and tolerability of SYN321 after a single injection into the knee joint.
  • The study will also look at how the body processes SYN321 and assess its preliminary effectiveness in treating knee osteoarthritis symptoms.[1]

Who Can Participate in the SYN321 Trial?

The trial has specific criteria for who can participate. Some key inclusion criteria are:
  • Adults aged 40 to 79 years
  • Diagnosed with knee osteoarthritis
  • Experiencing moderate to severe knee pain (rated 4-8 on a 0-10 scale)
  • Body Mass Index (BMI) between 18.5 and 35.0 kg/m²
There are also several exclusion criteria, including certain medical conditions, recent knee injections or surgeries, and use of specific medications. It’s important to note that these criteria are designed to ensure the safety of participants and the reliability of the study results.[1]

Potential Benefits and Risks

While the potential benefits of SYN321 are still being studied, it may offer relief from knee osteoarthritis symptoms, including pain and inflammation. However, as with any medical treatment, there may be risks involved. The study is designed to carefully monitor for any side effects or adverse reactions.[1]

What to Expect During the Trial

If you participate in the trial, you can expect:
  1. A single injection of either SYN321 or a placebo into your knee joint
  2. Regular check-ups and monitoring, including blood tests, urine tests, and electrocardiograms (ECGs)
  3. Daily self-assessments of your knee pain using a numerical rating scale
  4. Questionnaires about your knee function and quality of life
  5. Restrictions on using certain pain medications during the study period
The trial will last for 56 days after the injection, during which time you’ll be closely monitored for any changes in your condition or any side effects.[1]
Aspect Details
Drug Name SYN321
Condition Treated Knee Osteoarthritis
Administration Method Intra-articular injection
Main Study Objectives Safety, tolerability, systemic exposure, preliminary efficacy
Study Duration 56 days after injection
Key Measurements Daily pain levels, knee function, quality of life, use of rescue medication
Potential Effects Local analgesic, anti-inflammatory, potential lubricating effect

FAQ

  • What is SYN321 and how is it administered? SYN321 is a new drug being tested for knee osteoarthritis. It's given as an injection directly into the knee joint, which is called an intra-articular injection.
  • What is the main goal of the clinical trial for SYN321? The main goal is to check how safe and well-tolerated SYN321 is when injected into the knee.
  • Who can participate in this clinical trial? The trial is looking for people aged 40 to 79 who have been diagnosed with knee osteoarthritis. Participants need to have moderate to severe knee pain (rated 4-8 on a 0-10 scale) and meet other specific health criteria.
  • How long does the study last? The study lasts for 56 days (about 8 weeks) after the injection. During this time, participants will record their pain levels daily and complete questionnaires about their knee function and quality of life.
  • What are the potential benefits of SYN321? SYN321 is designed to have a local analgesic (pain-relieving) and anti-inflammatory effect. It may also have a lubricating effect on the knee joint. However, as this is a clinical trial, the actual benefits are still being studied.

Ongoing Clinical Trials on Syn321

  • Study on the Safety and Effects of SYN321 Injections for Patients with Knee Osteoarthritis

    Not recruiting

    1 1 1
    Investigated drugs:
    Sweden

Glossary

  • Osteoarthritis: A type of joint disease that results from breakdown of joint cartilage and underlying bone, causing pain and stiffness.
  • Intra-articular injection: A procedure where medication is injected directly into a joint space, in this case, the knee joint.
  • Clinical trial: A research study that tests how well new medical approaches work in people.
  • Double-blinded: A study design where neither the participants nor the researchers know who is receiving the actual treatment or a placebo.
  • Placebo: A substance with no active ingredients used in clinical trials to test the effectiveness of treatments.
  • Efficacy: How well a treatment works under ideal and controlled circumstances.
  • Systemic exposure: The presence and movement of a drug throughout the body after it's been administered.
  • Adverse events (AEs): Any unfavorable and unintended sign, symptom, or disease that occurs during the study, whether or not it is related to the treatment.
  • NRS (Numeric Rating Scale): A tool used to measure pain intensity on a scale from 0 (no pain) to 10 (worst possible pain).
  • KOOS (Knee Injury and Osteoarthritis Outcome Score): A questionnaire used to assess the patient's opinion about their knee and associated problems.

References

  1. http://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-syn321-injections-for-patients-with-knee-osteoarthritis/